NorthSea Therapeutics NASH Virtual KOL Call

Virtual, December 15, 2020

Virtual NASH KOL call with Dr. John Kastelein, MD, PhD and NorthSea Therapeutics

December 15, 11am-12pm


  • The importance of targeting cardiovascular risk factors in patients with NASH
  • The effects of icosabutate on cardiovascular risk factors in overweight, dyslipidemic subjects
  • Inflammation as a common driver of both NASH and CVD


John Kastelein, MD, PhD:
Dr. John Kastelein is professor of medicine, chairman of the department of vascular medicine, and holds the Strategic Chair of Genetics in Cardiovascular Disease at the Academic Medical Center of the University of Amsterdam. Dr. Kastelein is a member of the Steering Committees of numerous lipid lowering and cardiovascular intervention trials. His main interest is in the development of novel therapies for Cardiovascular Diseases and the genetic basis of dyslipidemia.

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

NorthSea Therapeutics
First-in class, oral, struc­tu­ral­ly en­gi­neered fat­ty acids [SE­FAs] ad­dress­ing NASH (pos­i­tive Ph2b in­ter­im re­sults) and as­so­ci­at­ed metabolic di­s­or­ders via unique tar­get­ing of path­ways reg­u­lat­ing metabolism, oxida­tive stress, in­flam­ma­tion, and fi­bro­sis. $40m Se­ries B (2020) with ven­Bio Part­n­ers (lead) and Sofin­no­va In­vest­ments. [more in­for­ma­tion]